You can read the text Altamimi A, Almutairi BA, Shaybah ME, Almahmoud LE, Mazyad AA, Afash AS, Alharbi NAO, Ghibban NW, Alharbi RJM, Almohaimeed MY, Ghazwani AH, Alrashidi AE, Altamimi A. Maternal disease control and pregnancy outcomes with anti-CD20 therapy versus natalizumab in multiple sclerosis: a systematic review.
You can read the text Altamimi A, Almutairi BA, Shaybah ME, Almahmoud LE, Mazyad AA, Afash AS, Alharbi NAO, Ghibban NW, Alharbi RJM, Almohaimeed MY, Ghazwani AH, Alrashidi AE, Altamimi A.
Maternal disease control and pregnancy outcomes with anti-CD20 therapy versus natalizumab in multiple sclerosis: a systematic review.
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
You can read the text Altamimi A, Almutairi BA, Shaybah ME, Almahmoud LE, Mazyad AA, Afash AS, Alharbi NAO, Ghibban NW, Alharbi RJM, Almohaimeed MY, Ghazwani AH, Alrashidi AE, Altamimi A. Maternal disease control and pregnancy outcomes with anti-CD20 therapy versus natalizumab in multiple sclerosis: a systematic review.
Open the app view to save this story, compare related coverage, and continue from the same source.